Multiple Sclerosis (MS) Emerging Therapy and TPP Insights

Thelansis’s “Multiple Sclerosis (MS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Multiple Sclerosis (MS) Overview

Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system characterized by chronic inflammation, demyelination, gliosis, and neuronal loss. Lesions occur at different times and sites, described as “disseminated in time and space.” The disease course varies, with most patients (70–80%) initially presenting with relapsing-remitting multiple sclerosis (RRMS), while 15–20% develop primary progressive multiple sclerosis (PPMS), and some may transition to secondary progressive multiple sclerosis (SPMS). Diagnosis requires evidence of at least two CNS inflammatory events, with relapses often partially or fully resolving. Current FDA-approved therapies—including fumarates such as diroximel fumarate, monoclonal antibodies like ocrelizumab, and other immunomodulators—aim to suppress inflammation and are most effective in early RRMS. Ocrelizumab remains the only FDA-approved disease-modifying therapy for PPMS, administered intravenously every six months. Advances in 2025 highlight a shift toward therapies targeting remyelination and neuroprotection, expanding treatment beyond immune suppression.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)